Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.

Dr David J. Kerr reviews HDAC and immune checkpoint inhibitors, therapies on the horizon for a subset of patients with colorectal cancers.

Dr Maurie Markman reports on high response rates to rucaparib therapy for ovarian cancer and looks forward to future research efforts using this PARP inhibitor.

Colorectal cancer is the second most common cause of cancer death in the Latino population. Drs John Marshall and Marcia Cruz-Correa discuss which factors are at play.

Dr David Kerr views a case of engineered T cells in a CRC patient with pulmonary metastases as an example of a single-patient clinical trial, neatly illustrating the potential of precision medicine.

Dr Jeffrey Weber assesses the benefit of immunotherapies in two rare subtypes of melanoma and finds that rates of survival and duration of response trail well behind those associated with cutaneous melanoma.

Although LDH is a negative prognostic factor in melanoma, patients who receive checkpoint inhibitors may still have responses of long duration even when their LDH level is high.

Tumor location, whether on the right or left side of the colon, seems to affect the prognosis and aggressiveness of recurrent colorectal cancer.

Dr Maurie Markman discusses the results of an RRSO surgery study showing a 1% incidence rate in long-term follow-up of subsequent peritoneal cancer.

Dr Mark Kris reviews the challenges of using newly approved immunotherapies for lung cancer patients, especially how to identify patients who will benefit and monitor their progress.